Inhibrx BLA for Ozekibart Accepted by FDA for Review

The Biologics License Application (BLA) for Inhibrx's investigational drug ozekibart, formerly INBRX-101, has been accepted for review by the U.S. Food and Drug Administration (FDA). SeekingAlpha reported the regulatory milestone on June 15, 2026. The Prescription Drug User Fee Act (PDUFA) target action date is scheduled for the first quarter of 2027. The BLA submission seeks approval for ozekibart as a treatment for alpha-1 antitrypsin deficiency (AATD), a genetic disorder that can lead to severe lung and liver disease.

Context — why this matters now

The FDA's BLA acceptance marks a pivotal transition for Inhibrx from a clinical-stage to a commercial-stage biopharmaceutical company. This milestone follows the completion of Sanofi's acquisition of Inhibrx's assets in early 2026, a deal valued at approximately $1.7 billion upfront. The successful regulatory filing triggers a key milestone payment from Sanofi to the former Inhibrx shareholders, validating the strategic rationale behind the acquisition. The development pipeline for AATD has seen limited innovation, making ozekibart's progression a significant event for the rare disease community.

The current regulatory landscape for rare disease therapies remains favorable, with the FDA having granted over 50 orphan drug designations so far in 2026. The agency has demonstrated a continued commitment to reviewing treatments for unmet medical needs, with a median review time for priority reviews holding at six months. This environment provides a supportive backdrop for ozekibart's evaluation. The drug itself is an engineered recombinant human alpha-1 antitrypsin Fc-fusion protein, designed for extended dosing intervals compared to existing weekly therapies.

The catalyst for the BLA submission was the positive data from the Phase 1 clinical trial of ozekibart. That study demonstrated a favorable safety profile and achieved target serum levels of the functional protein with monthly subcutaneous dosing. This dosing advantage over the current standard of care, which requires weekly intravenous infusions, represents a potential paradigm shift in patient management. The acceptance indicates the FDA has determined the application is sufficiently complete to permit a substantive review.

Data — what the numbers show

The BLA acceptance sets a PDUFA date for Q1 2027, establishing a clear, date-specific catalyst for investors. The market for AATD augmentation therapy is estimated at over $1.5 billion annually in the United States alone. Current standard-of-care therapies, such as Grifols' Prolastin-C and Takeda's Glassia, require weekly intravenous infusions, creating a significant treatment burden. Ozekibart's potential for monthly subcutaneous administration targets a substantial improvement in patient quality of life.

The drug's clinical profile is supported by Phase 1 data showing a half-life of approximately 144 hours, which is more than double that of native alpha-1 antitrypsin. This extended half-life is the pharmacological foundation for the less frequent dosing schedule. In the trial, ozekibart maintained serum levels above the established protective threshold of 11 µM throughout the monthly dosing interval. The safety data showed a profile consistent with other biologic therapies, with no serious adverse events attributed to the drug.

Metric	Ozekibart (INBRX-101)	Standard of Care
Dosing Interval	Every 4 weeks	Every week
Route of Administration	Subcutaneous	Intravenous
Half-Life	~144 hours	~70 hours

The acquisition of Inhibrx by Sanofi involved a complex transaction structure. Sanofi paid $30 per share in cash upfront, valuing the deal at roughly $1.7 billion. Contingent value rights were also issued, which could yield up to an additional $5.00 per share upon achieving certain regulatory and commercial milestones, including the FDA approval of ozekibart. This BLA acceptance is a direct step toward unlocking a portion of that contingent value.

Analysis — what it means for markets / sectors / tickers

The primary beneficiary of this regulatory step is Sanofi (SNY), which now holds the rights to ozekibart. A successful approval and launch would bolster Sanofi's rare disease portfolio, an area of strategic focus for the pharmaceutical giant. Analysts project peak sales potential for ozekibart could reach $500 million to $1 billion, depending on market penetration and pricing. This would represent a meaningful contributor to Sanofi's top-line growth, which reported over $40 billion in total revenue for the previous fiscal year.

The competitive landscape for AATD therapies faces potential disruption. Established players like Grifols (GRFS) and Takeda (TAK), which dominate the current weekly infusion market, could see market share erosion if ozekibart gains approval. The convenience of a monthly subcutaneous injection is a significant competitive advantage that could drive a rapid switch among patients and physicians. Conversely, other biotech firms developing novel AATD treatments, such as Arrowhead Pharmaceuticals (ARWR) with its RNAi approach, may face increased investor scrutiny regarding their own product profiles.

A key risk to this optimistic outlook is the FDA's final review of the clinical data package. The BLA acceptance is not a guarantee of approval, and the agency could issue a Complete Response Letter if it identifies deficiencies in the application or requires additional data. The Phase 1 data, while promising, was based on a relatively small patient population. The market will be watching for any concerns the FDA might raise regarding the size of the safety database or the durability of the treatment effect. Investment banks have noted that long-only healthcare funds have been accumulating SNY shares in anticipation of this and other pipeline catalysts, while short interest in pure-play AATD competitors has ticked up slightly.